

**Structural landscape of new salts of anti-histamine drug bilastine: Implications in physicochemical properties and anti-cancer activity against skin cancer**

Manimurugan Kanagavel<sup>a,c</sup>, Rajan Marystella Sparjan Samuvel<sup>b,c</sup>, Vaikundamoorthy Ramalingam<sup>b,c\*</sup>, Sunil Kumar Nechipadappu<sup>a,c\*</sup>

<sup>a</sup> Centre for X-ray Crystallography, Department of Analytical & Structural Chemistry, CSIR-Indian Institute of Chemical Technology, Hyderabad, India – 500 007.

<sup>b</sup> Department of Natural Products and Medicinal Chemistry, CSIR-Indian Institute of Chemical Technology, Hyderabad, India – 500 007.

<sup>c</sup> Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, 201002, India

\*Corresponding authors: *nsunilkumar@iict.res.in* and *ramalingam@iict.res.in*


**Table of Contents**

S. No.	Table/Figure No	Table/Figure caption
1.	Table S1	Hydrogen-bond geometry of BLN salts
2.	Figure S1	UPLC chromatogram of BLN
3.	Figure S2	$^1\text{H}$ NMR of $\text{BLN}^+ \cdot \text{H}_2\text{PO}_4^-$
4.	Figure S3	$^{13}\text{C}$ NMR overlay of BLN and $\text{BLN}^+ \cdot \text{H}_2\text{PO}_4^-$
5.	Figure S4	CHN analysis plot
6.	Figure S5	Crystal packing of $\text{BLN}^+ \cdot \text{Cl} \cdot 3\text{H}_2\text{O}$
7.	Figure S6	Crystal packing diagram of $\text{BLN}^+ \cdot \text{Cl} \cdot 4\text{H}_2\text{O}$
8.	Figure S7	Crystal packing diagram of $\text{BLN}^+ \cdot \text{Br} \cdot \text{H}_2\text{O}$
9.	Figure S8	Crystal packing diagram of $\text{BLN}^{2+} \cdot \text{NO}_3^{2-} \cdot \text{H}_2\text{O}$
10.	Figure S9	Crystal packing diagram of $\text{BLN}^{2+} \cdot \text{SO}_4^{2-} \cdot 4\text{H}_2\text{O}$
11.	Figure S10	Crystal packing diagram of $\text{BLN}^+ \cdot \text{H}_2\text{PO}_4^- \cdot 2\text{MeOH}$
12.	Figures S11	Crystal packing diagram of $\text{BLN}^+ \cdot \text{H}_2\text{PO}_4^- \cdot \text{Cl} \cdot 3\text{H}_2\text{O}$
13.	Figure S12-15	Powder XRD pattern overlay of BLN salts with simulated patterns
14.	Figure S16-19	Powder XRD pattern overlay of stability samples of BLN salts with simulated patterns
15.	Figure S20	Powder XRD overlay of $\text{BLN}^+ \cdot \text{H}_2\text{PO}_4^-$ after heating to first endotherm, $\text{BLN}^+ \cdot \text{H}_2\text{PO}_4^-$ experimental with BLN Form-I
16.	Figure S21	DSC plot of $\text{BLN}^+ \cdot \text{H}_2\text{PO}_4^-$ preheated sample up to 200 °C
17.	Figure S22-25	FT-IR spectrum of BLN salts
18.	Figure S26-27	BLN standard linearity plot
19.	Figure S28-29	Powder XRD overlays after solubility studies (pH-1.2 and 6.8).
20.	Figure S30	DSC-TGA plot of $\text{BLN}^+ \cdot \text{Br} \cdot \text{H}_2\text{O}$ after pH 6.8 solubility study
21.	Figure S31	$^1\text{H}$ NMR spectrum of $\text{BLN}^+ \cdot \text{Br} \cdot \text{H}_2\text{O}$ after pH 6.8 solubility study


**Table S1** Hydrogen-bond geometry of BLN salts ( $\text{\AA}$ ,  $^\circ$ ).

D—H···A	D—H	H···A	D···A	D—H···A
<b>BLN<sup>+</sup>-Cl<sup>-</sup>-3H<sub>2</sub>O</b>				
O1W—H2W···ClO1 <sup>i</sup>	0.83 (3)	2.45 (3)	3.2700 (15)	175 (2)
O3W—H5W···ClO1 <sup>i</sup>	0.90 (3)	2.41 (3)	3.3016 (14)	171 (2)
O2W—H3W···ClO1 <sup>ii</sup>	0.84 (3)	2.36 (3)	3.1851 (14)	167 (2)
O2W—H4W···N2 <sup>ii</sup>	0.88 (2)	2.02 (2)	2.8896 (17)	173 (2)
O3W—H6W···O2W	0.92 (3)	2.04 (3)	2.9616 (19)	172 (2)
N3—H3N···ClO1	0.944 (18)	2.139 (18)	3.0766 (13)	171.9 (15)
O3—H3O···O1W	0.85 (2)	1.81 (2)	2.6536 (17)	174 (2)
O1W—H1W···O2W	0.87 (3)	1.95 (3)	2.8215 (17)	172 (2)
Symmetry codes: (i) $-x+3/2, y+1/2, -z+3/2$ ; (ii) $x-1/2, -y+1/2, z+1/2$ .				
<b>BLN<sup>+</sup>-Cl<sup>-</sup>-4H<sub>2</sub>O</b>				
O3—H3O···N2 <sup>i</sup>	0.89 (5)	1.73 (5)	2.594 (3)	164 (4)
O1W—H1W···O2W	0.81 (2)	1.95 (3)	2.744 (4)	166 (4)
O1W—H2W···Cl1 <sup>ii</sup>	0.82 (2)	2.32 (3)	3.113 (3)	163 (4)
O2W—H3W···O3W	0.88 (2)	1.88 (3)	2.734 (4)	162 (4)
O2W—H4W···O4W	0.89 (2)	1.85 (3)	2.744 (4)	174 (4)
O3W—H5W···O2 <sup>iii</sup>	0.84 (2)	2.03 (3)	2.854 (3)	165 (4)
O3W—H6W···Cl1 <sup>iv</sup>	0.87 (3)	2.27 (3)	3.137 (3)	173 (5)
O4W—H7W···O1 <sup>iv</sup>	0.95 (6)	1.95 (6)	2.857 (4)	159 (5)
O4W—H8W···Cl1	0.79 (4)	2.33 (4)	3.117 (3)	175 (4)
N3—H3N···O1W	0.86 (4)	1.94 (4)	2.786 (3)	168 (4)
Symmetry codes: (i) $x, y, z+1$ ; (ii) $x+1, y, z$ ; (iii) $-x+2, y+1/2, -z+2$ ; (iv) $-x+1, y+1/2, -z+1$ .				
<b>BLN<sup>+</sup>-Br<sup>-</sup>-H<sub>2</sub>O</b>				
O3—H3O···O2 <sup>i</sup>	0.80 (2)	1.83 (2)	2.6271 (16)	177 (2)
O1W—H1W···N2	0.78 (3)	2.09 (3)	2.8707 (18)	177 (3)
O1W—H2W···Br1	0.77 (2)	2.60 (2)	3.3754 (13)	177 (2)
N3—H3N···Br1	0.89 (2)	2.37 (2)	3.2475 (12)	165.8 (17)
Symmetry code: (i) $-x+1, -y, -z+1$ .				
<b>BLN<sup>2+</sup>-NO<sub>3</sub><sup>2-</sup>-H<sub>2</sub>O</b>				
N3—H3N···O4 <sup>i</sup>	0.95 (3)	2.48 (3)	2.985 (3)	113 (2)
N2—H2N···N4	0.89 (2)	2.56 (2)	3.426 (4)	162 (3)
N2—H2N···O5	0.89 (2)	2.52 (3)	3.216 (4)	136 (3)
N2—H2N···O6	0.89 (2)	1.88 (2)	2.753 (4)	167 (3)
N3—H3N···O1W	0.95 (3)	1.92 (3)	2.823 (4)	157 (3)
O3—H3O···N5	0.84	2.48	3.321 (8)	176
O3—H3O···O7	0.84	2.35	3.111 (12)	152
O3—H3O···O8	0.84	1.80	2.544 (6)	147
O1W—H1W···O6	0.86 (1)	2.10 (3)	2.873 (5)	150 (6)
Symmetry code: (i) $-x+1, -y+1, -z+1$ .				
<b>BLN<sup>2+</sup>-SO<sub>4</sub><sup>2-</sup>-4H<sub>2</sub>O</b>				
O6—H6O···S1 <sup>i</sup>	0.84	2.72	3.510 (4)	157
O6—H6O···O5 <sup>i</sup>	0.84	1.74	2.570 (5)	168
O3W—H5W···S2 <sup>iii</sup>	0.86 (1)	3.00 (3)	3.783 (5)	152 (6)
O4W—H7W···O3 <sup>iii</sup>	0.86 (1)	1.99 (1)	2.842 (6)	173 (6)
O4W—H8W···O8 <sup>iv</sup>	0.86 (1)	2.06 (3)	2.823 (8)	148 (6)
O9—H9O···O3W	0.86 (1)	1.65 (1)	2.509 (7)	175 (8)
O1W—H1W···S2	0.86 (1)	2.90 (1)	3.758 (6)	175 (10)
O1W—H1W···O11	0.86 (1)	1.86 (5)	2.645 (17)	151 (10)
O1W—H2W···O2W	0.86 (1)	2.10 (10)	2.726 (10)	130 (11)
O3W—H6W···O4W	0.86 (1)	1.81 (1)	2.670 (6)	172 (6)


N2—H2···O5	0.88	1.90	2.780 (5)	173
N3—H3···S1	1.00	2.94	3.883 (4)	158
N3—H3···O4	1.00	1.83	2.779 (5)	157
O2—H2O···O1W	0.99 (7)	1.56 (7)	2.525 (7)	163 (6)
Symmetry codes: (i) $x, -y+3/2, z-1/2$ ; (ii) $-x+1, -y+1, -z-2$ ; (iii) $-x, -y+1, -z-2$ ; (iv) $-x, -y+1, -z-3$ .				
<b>BLN<sup>+</sup>·H<sub>2</sub>PO<sub>4</sub><sup>-</sup>·2MeOH</b>				
N3—H3N···O7 <sup>i</sup>	0.85 (5)	1.83 (5)	2.683 (4)	178 (5)
O2—H2O···O5	0.87 (7)	1.78 (8)	2.613 (4)	160 (7)
O4—H4O···O7 <sup>ii</sup>	0.83 (5)	1.74 (5)	2.554 (4)	169 (5)
O6—H6O···N2 <sup>iii</sup>	0.83 (6)	1.83 (6)	2.663 (4)	174 (5)
O8a—H8Oa···O5	0.84	2.04	2.776 (11)	145
O9—H9O···O8	0.84	2.08	2.794 (16)	142
Symmetry codes: (i) $-x+2, -y+1, -z+1$ ; (ii) $-x+2, -y+1, -z$ ; (iii) $x, y, z-1$ .				
<b>BLN<sup>+</sup>·H<sub>2</sub>PO<sub>4</sub><sup>-</sup>·Cl<sup>-</sup>·3H<sub>2</sub>O</b>				
O1W—H2W···Cl1 <sup>i</sup>	0.98 (2)	2.17 (2)	3.1378 (12)	172.6 (18)
O2W—H4W···O1B <sup>ii</sup>	0.86 (2)	2.05 (2)	2.9073 (15)	172 (2)
N3B—H3NB···Cl1	0.900 (17)	2.276 (18)	3.1624 (12)	168.3 (14)
O2B—H2OB···O1	1.04 (5)	1.44 (5)	2.4793 (16)	172 (3)
O2B—H2OB···O3	1.04 (5)	2.65 (4)	3.2955 (14)	119 (2)
O1—H1O···O2B	0.64 (5)	1.84 (5)	2.4793 (16)	174 (6)
O1—H1O···O3B	0.64 (5)	2.86 (5)	3.3183 (16)	131 (5)
O1—H1O···O2B	0.64 (5)	1.84 (5)	2.4793 (16)	174 (6)
O3—H3O···O3B	0.93 (2)	1.64 (3)	2.5709 (15)	176 (2)
O4—H4O···O2A	0.85 (2)	1.80 (2)	2.647 (3)	176 (2)
O1W—H1W···O2W	0.84 (2)	1.90 (2)	2.7316 (16)	172 (2)
O2W—H3W···N2A	0.91 (2)	1.99 (2)	2.8971 (16)	175 (2)
O3W—H5W···N2B	0.94 (2)	1.95 (2)	2.8562 (16)	162 (2)
O3W—H6W···Cl1	0.92 (2)	2.32 (2)	3.2383 (14)	172.3 (19)
N3A—H3NA···O1W	0.906 (17)	1.821 (18)	2.7253 (16)	176.2 (15)
O3A—H3OA···O2	0.99 (2)	1.49 (3)	2.4697 (14)	173 (2)
Symmetry codes: (i) $x, y-1, z-1$ ; (ii) $x-1, y-1, z-1$ .				



**Fig. S1** UPLC chromatogram of BLN.




**Fig. S2**  $^1\text{H}$  NMR of  $\text{BLN}^+ \cdot \text{H}_2\text{PO}_4^-$  (400 MHz, DMSO-d6)  $\delta$ -ppm: 0.99- 1.02 (t, 3H), 1.46 (S, 6H), 1.97- 2.07 (m, 4H), 2.53- 2.55 (m, 2H), 2.86-2.87 (d, 4H), 3.16-3.20 (t, 1H), 3.30- 3.32 (m, 2H), 3.33-3.38 (q,2H), 3.65- 3.67 (t, 2H), 4.41-4.43 (t, 2H), 7.14-7.30 (m, 6H), 7.53-7.58 (m, 2H).




**Fig. S3**  $^{13}\text{C}$  NMR overlay of BLN and  $\text{BLN}^+\text{-H}_2\text{PO}_4^-$  (100 MHz, DMSO-d6)  $\delta$ -ppm

**BLN $^+$ -H<sub>2</sub>PO<sub>4</sub><sup>-</sup>**: 15.39, 26.93, 31.08, 32.49, 43.62, 45.97, 52.49, 58.34, 66.25, 68.83, 110.82, 118.92, 121.88, 122.12, 126.13, 129.09, 135.12, 137.45, 142.55, 142.55, 158.28, 178.48.


**BLN**: 15.41, 26.91, 31.51, 32.75, 33.93, 43.55, 45.90, 53.62, 60.58, 66.22, 68.93, 110.67, 118.90, 121.68, 121.87, 125.93, 129.02, 135.22, 139.07, 142.78, 143.07, 159.13, 178.19.




**Fig. S4** CHN analysis plot of BLN salts a)  $\text{BLN}^+ \cdot \text{Cl}^- \cdot 3\text{H}_2\text{O}$ , b)  $\text{BLN}^+ \cdot \text{Br}^- \cdot \text{H}_2\text{O}$ , c)  $\text{BLN}^{2+} \cdot \text{NO}_3^{2-} \cdot \text{H}_2\text{O}$ , and d)  $\text{BLN}^+ \cdot \text{H}_2\text{PO}_4^-$ .




**Fig. S5** The crystal packing of  $\text{BLN}^+ \cdot \text{Cl}^- \cdot 3\text{H}_2\text{O}$  showing the symmetry codes of hydrogen bond interaction.




**Fig. S6** The crystal packing diagram of  $\text{BLN}^+\text{-Cl}^- \cdot 4\text{H}_2\text{O}$  showing the hydrogen bond interactions and ring motifs.




**Fig. S7** The crystal packing diagram of  $\text{BLN}^+\text{-Br}^- \cdot \text{H}_2\text{O}$  showing the hydrogen bond interactions and ring motifs.




**Fig. S8** The crystal packing diagram of  $\text{BLN}^{2+}\text{-NO}_3^{2-}\text{-H}_2\text{O}$  showing the hydrogen bond interactions and ring motifs.




**Fig. S9** The crystal packing diagram of  $\text{BLN}^{2+}\text{-SO}_4^{2-}\text{-4H}_2\text{O}$  showing the hydrogen bond interactions and ring motifs.




**Fig. S10** The crystal packing diagram of  $\text{BLN}^+ \cdot \text{H}_2\text{PO}_4^- \cdot 2\text{MeOH}$  showing the hydrogen bond interactions and ring motifs.




**Fig. S11** The crystal packing diagram of  $\text{BLN}^+ \cdot \text{H}_2\text{PO}_4^- \cdot \text{Cl}^- \cdot 3\text{H}_2\text{O}$  showing the hydrogen bond interactions and ring motifs.




**Fig. S12** PXRD powder pattern overlay of (a)  $\text{BLN}^+ \cdot \text{Cl}^- \cdot 3\text{H}_2\text{O}$  simulated and (b)  $\text{BLN}^+ \cdot \text{Cl}^- \cdot 3\text{H}_2\text{O}$  experimental with (c) BLN Form-I.




**Fig. S13** PXRD powder pattern overlay of (a)  $\text{BLN}^+ \cdot \text{Br} \cdot \text{H}_2\text{O}$  simulated and (b)  $\text{BLN}^+ \cdot \text{Br} \cdot \text{H}_2\text{O}$  experimental with (c) BLN Form-I.




**Fig. S14** PXRD powder pattern overlay of (a)  $\text{BLN}^{2+}\text{-NO}_3^{2-}\text{-H}_2\text{O}$  simulated and (b)  $\text{BLN}^{2+}\text{-NO}_3^{2-}\text{-H}_2\text{O}$  experimental with (c) BLN Form-I.




**Fig. S15** PXRD powder pattern overlay of (a) BLN Form-I (b)  $\text{BLN}^+\text{-H}_2\text{PO}_4^-$  experimental (c)  $\text{BLN}^+\text{-H}_2\text{PO}_4^-$ -2MeOH simulated.




**Fig. S16** PXRD powder pattern overlay of stability samples at room temperature (a)  $\text{BLN}^+\text{-Cl}^- \cdot 3\text{H}_2\text{O}$  simulated (b)  $\text{BLN}^+\text{-Cl}^- \cdot 3\text{H}_2\text{O}$  experimental after one month (c)  $\text{BLN}^+\text{-Cl}^- \cdot 3\text{H}_2\text{O}$  experimental after two months d)  $\text{BLN}^+\text{-Cl}^- \cdot 3\text{H}_2\text{O}$  experimental after three months.




**Fig. S17** PXRD powder pattern overlay of stability samples at room temperature (a)  $\text{BLN}^+\text{-Br}^- \cdot \text{H}_2\text{O}$  simulated and (b)  $\text{BLN}^+\text{-Br}^- \cdot \text{H}_2\text{O}$  experimental after one month (c)  $\text{BLN}^+\text{-Br}^- \cdot \text{H}_2\text{O}$  experimental after two months d)  $\text{BLN}^+\text{-Br}^- \cdot \text{H}_2\text{O}$  experimental after three months.




**Fig. S18** PXRD powder pattern overlay of stability samples at room temperature (a) BLN<sup>2+</sup>-NO<sub>3</sub><sup>2-</sup>-H<sub>2</sub>O simulated and (b) BLN<sup>2+</sup>-NO<sub>3</sub><sup>2-</sup>-H<sub>2</sub>O experimental after one month (c) BLN<sup>2+</sup>-NO<sub>3</sub><sup>2-</sup>-H<sub>2</sub>O experimental after two months d) BLN<sup>2+</sup>-NO<sub>3</sub><sup>2-</sup>-H<sub>2</sub>O experimental after three months (\* indicates the unaccounted peak).




**Fig. S19** PXRD powder pattern overlay of (a) BLN<sup>+</sup>-H<sub>2</sub>PO<sub>4</sub><sup>-</sup> experimental initial (b) BLN<sup>+</sup>-H<sub>2</sub>PO<sub>4</sub><sup>-</sup> experimental after one month (c) BLN<sup>+</sup>-H<sub>2</sub>PO<sub>4</sub><sup>-</sup> experimental after two months d) BLN<sup>+</sup>-H<sub>2</sub>PO<sub>4</sub><sup>-</sup> experimental after three months.




**Fig. S20** PXRD powder pattern overlay of stability samples at room temperature (a)  $\text{BLN}^+ \text{-H}_2\text{PO}_4^-$  experimental and (b)  $\text{BLN}^+ \text{-H}_2\text{PO}_4^-$  after heating to first endotherm ( $200^\circ\text{C}$ ) with (c)  $\text{BLN}$  Form-I.




**Fig. S21** DSC plot of  $\text{BLN}^+ \text{-H}_2\text{PO}_4^-$  preheated sample (up to first endotherm).




**Fig. S22** FT-IR spectrum of  $\text{BLN}^+\text{-Cl}^- \cdot 3\text{H}_2\text{O}$ .




**Fig. S23** FT-IR spectrum of  $\text{BLN}^+\text{-Br}^- \cdot \text{H}_2\text{O}$ .




**Fig. S24** FT-IR spectrum of BLN<sup>2+</sup>-NO<sub>3</sub><sup>2-</sup>-H<sub>2</sub>O.




**Fig. S25** FT-IR spectrum of BLN<sup>+</sup>-H<sub>2</sub>PO<sub>4</sub><sup>-</sup>.




**Fig. S26** BLN linearity plot in buffer pH-1.2 at 272 nm.




**Fig. S27** BLN linearity plot in buffer pH-6.8 at 275 nm.




**Fig. S28** PXRD overlay of solubility samples after 24 hrs a)  $\text{BLN}^+ \cdot \text{Cl}^- \cdot 3\text{H}_2\text{O}$  pH-1.2 before solubility b)  $\text{BLN}^+ \cdot \text{Cl}^- \cdot 3\text{H}_2\text{O}$  pH-1.2 after solubility c)  $\text{BLN}^+ \cdot \text{Br}^- \cdot \text{H}_2\text{O}$  pH-1.2 before solubility d)  $\text{BLN}^+ \cdot \text{Br}^- \cdot \text{H}_2\text{O}$  pH-1.2 after solubility e)  $\text{BLN}^{2+} \cdot \text{NO}_3^{2-} \cdot \text{H}_2\text{O}$  pH-1.2 before solubility f)  $\text{BLN}^{2+} \cdot \text{NO}_3^{2-} \cdot \text{H}_2\text{O}$  pH-1.2 after solubility g)  $\text{BLN}^+ \cdot \text{H}_2\text{PO}_4^-$  pH-1.2 before solubility h)  $\text{BLN}^+ \cdot \text{H}_2\text{PO}_4^-$  pH-1.2 after solubility i)  $\text{BLN}^+ \cdot \text{H}_2\text{PO}_4^- \cdot \text{Cl}^- \cdot 3\text{H}_2\text{O}$  experimental.



**Fig. S29** PXRD overlay of solubility samples after 24 hrs a) BLN Form-I b)  $\text{BLN}^+ \cdot \text{Cl}^- \cdot 3\text{H}_2\text{O}$  pH 6.8 after solubility c)  $\text{BLN}^+ \cdot \text{Br}^- \cdot \text{H}_2\text{O}$  pH-6.8 after solubility d)  $\text{BLN}^{2+} \cdot \text{NO}_3^{2-} \cdot \text{H}_2\text{O}$  pH-6.8 after solubility e)  $\text{BLN}^+ \cdot \text{H}_2\text{PO}_4^-$  pH-6.8 after solubility.



**Fig. S30** DSC-TGA plot of  $\text{BLN}^+ \cdot \text{Br} \cdot \text{H}_2\text{O}$  after pH-6.8 solubility.



**Fig. S31**  $^1\text{H}$  NMR spectrum of  $\text{BLN}^+ \cdot \text{Br} \cdot \text{H}_2\text{O}$  pH-6.8 after solubility.